Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) shares were down 4% during trading on Tuesday . The stock traded as low as $1.19 and last traded at $1.19. Approximately 215,415 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 397,314 shares. The stock had previously closed at $1.24.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on CLYM shares. BTIG Research initiated coverage on Climb Bio in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. Oppenheimer started coverage on shares of Climb Bio in a report on Friday, June 6th. They issued an "outperform" rating and a $10.00 price objective on the stock.
Get Our Latest Stock Report on CLYM
Climb Bio Stock Up 1.6%
The stock has a market cap of $86.50 million, a P/E ratio of -0.54 and a beta of -0.13. The firm has a 50 day moving average price of $1.25 and a 200 day moving average price of $1.48.
Climb Bio (NASDAQ:CLYM - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.16). Equities analysts predict that Climb Bio, Inc. will post -1.57 earnings per share for the current fiscal year.
Institutional Trading of Climb Bio
Institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. bought a new position in shares of Climb Bio during the 1st quarter valued at about $147,000. AQR Capital Management LLC bought a new position in shares of Climb Bio in the 1st quarter valued at about $27,000. Allostery Investments LP purchased a new position in Climb Bio in the first quarter worth about $299,000. ADAR1 Capital Management LLC bought a new stake in Climb Bio during the first quarter worth approximately $146,000. Finally, RA Capital Management L.P. purchased a new stake in Climb Bio during the first quarter valued at approximately $38,332,000. Hedge funds and other institutional investors own 69.76% of the company's stock.
About Climb Bio
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Further Reading
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
